Literature DB >> 18413441

EULAR recommendations for the management of large vessel vasculitis.

C Mukhtyar1, L Guillevin, M C Cid, B Dasgupta, K de Groot, W Gross, T Hauser, B Hellmich, D Jayne, C G M Kallenberg, P A Merkel, H Raspe, C Salvarani, D G I Scott, C Stegeman, R Watts, K Westman, J Witter, H Yazici, R Luqmani.   

Abstract

OBJECTIVES: To develop European League Against Rheumatism (EULAR) recommendations for the management of large vessel vasculitis.
METHODS: An expert group (10 rheumatologists, 3 nephrologists, 2 immunolgists, 2 internists representing 8 European countries and the USA, a clinical epidemiologist and a representative from a drug regulatory agency) identified 10 topics for a systematic literature search through a modified Delphi technique. In accordance with standardised EULAR operating procedures, recommendations were derived for the management of large vessel vasculitis. In the absence of evidence, recommendations were formulated on the basis of a consensus opinion.
RESULTS: Seven recommendations were made relating to the assessment, investigation and treatment of patients with large vessel vasculitis. The strength of recommendations was restricted by the low level of evidence and EULAR standardised operating procedures.
CONCLUSIONS: On the basis of evidence and expert consensus, management recommendations for large vessel vasculitis have been formulated and are commended for use in everyday clinical practice.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18413441     DOI: 10.1136/ard.2008.088351

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  150 in total

1.  [Therapy of vasculitides: according to recommendations of the European League Against Rheumatism (EULAR) and European Vasculitis Study Group (EUVAS)].

Authors:  J U Holle; F Moosig; W L Gross
Journal:  Internist (Berl)       Date:  2011-06       Impact factor: 0.743

2.  Spontaneous fusion between cancer cells and endothelial cells.

Authors:  K Mortensen; J Lichtenberg; P D Thomsen; L-I Larsson
Journal:  Cell Mol Life Sci       Date:  2004-08       Impact factor: 9.261

3.  The impact of 18F-FDG PET on the management of patients with suspected large vessel vasculitis.

Authors:  Martin Fuchs; Matthias Briel; Thomas Daikeler; Ulrich A Walker; Helmut Rasch; Scott Berg; Quinn K T Ng; Heike Raatz; David Jayne; Ina Kötter; Daniel Blockmans; Maria C Cid; Sergio Prieto-González; Peter Lamprecht; Carlo Salvarani; Zaharenia Karageorgaki; Richard Watts; Raashid Luqmani; Jan Müller-Brand; Alan Tyndall; Martin A Walter
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-11-10       Impact factor: 9.236

4.  Parameters related to a positive test result for FDG PET(/CT) for large vessel vasculitis: a multicenter retrospective study.

Authors:  G A Hooisma; H Balink; P M Houtman; R H J A Slart; K D F Lensen
Journal:  Clin Rheumatol       Date:  2012-02-10       Impact factor: 2.980

Review 5.  Giant cell arteritis: epidemiology, diagnosis, and management.

Authors:  Miguel A Gonzalez-Gay; Cristina Martinez-Dubois; Mario Agudo; Orlando Pompei; Ricardo Blanco; Javier Llorca
Journal:  Curr Rheumatol Rep       Date:  2010-12       Impact factor: 4.592

Review 6.  [Childhood vasculitis].

Authors:  J B Kümmerle-Deschner; J Thomas; S M Benseler
Journal:  Z Rheumatol       Date:  2015-12       Impact factor: 1.372

7.  Prednisolone combined with adjunctive immunosuppression is not superior to prednisolone alone in terms of efficacy and safety in giant cell arteritis: meta-analysis.

Authors:  M Yates; Y K Loke; R A Watts; A J MacGregor
Journal:  Clin Rheumatol       Date:  2013-09-12       Impact factor: 2.980

8.  [Recommendations of the European League Against Rheumatism (EULAR) for the treatment of "large-vessel vasculitides"].

Authors:  E Wipfler-Freissmuth; F Moosig; M Schirmer
Journal:  Z Rheumatol       Date:  2009-05       Impact factor: 1.372

9.  Predictors of relapse and treatment outcomes in biopsy-proven giant cell arteritis: a retrospective cohort study.

Authors:  Cristian Labarca; Matthew J Koster; Cynthia S Crowson; Ashima Makol; Steven R Ytterberg; Eric L Matteson; Kenneth J Warrington
Journal:  Rheumatology (Oxford)       Date:  2015-09-18       Impact factor: 7.580

10.  [Personalized medicine in the choice of conventional immunosuppressants and disease modifying antirheumatic drugs].

Authors:  C Fiehn; G Keyßer; H-M Lorenz
Journal:  Z Rheumatol       Date:  2013-02       Impact factor: 1.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.